Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs
- 22 December 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (6) , 763-778
Abstract
Cisplatin is a platinum‐based chemotherapeutic drug used to treat many types of cancer. The aim of this study was to develop a population pharmacokinetic model that incorporates plasma unbound and bound platinum levels. Cancer patients undergoing their first or second cycle of cisplatin‐containing chemotherapy (n = 33) were prospectively randomized to receive a 5‐hydroxytryptamine (5‐HT3) antagonist (5‐HT3A) antiemetic (ondansetron, granisetron, or palonosetron) followed by blood collection over 10 days. Total and unbound platinum levels were quantified using inductively coupled plasma mass spectrometry. Plasma concentrations of bound and unbound platinum were used to develop a nonlinear mixed‐effect pharmacokinetic model in Phoenix NLME (v8.3, Certara Inc.). A stepwise search was used to screen covariates that influenced pharmacokinetic parameters. A compartment for bound platinum was added to a two‐compartment unbound platinum model to create a combined platinum model. The volume of the central compartment for unbound platinum (V1_u) was significantly impacted by previous cisplatin exposure and the intercompartmental clearance of unbound platinum (CL2_u) was significantly influenced by concomitant lorazepam use. The models also suggested ondansetron‐ and granisetron‐treated subjects had a 331% and 114% increase, respectively, in circulating exposures to unbound platinum than palonosetron‐treated subjects. The results suggest platinum pharmacokinetics are altered by concomitant 5‐HT3A antiemetic use, concomitant lorazepam use, and previous exposure to cisplatin. Ondansetron and granisetron co‐treatment increased unbound platinum exposure compared to palonosetron co‐treatment, suggesting that palonosetron may be a preferred 5‐HT3A to reduce the risk of cisplatin‐induced kidney injury.Keywords
Funding Information
- National Cancer Institute (P30 CA008748, P30 CA046934, P30 CA072720)
- National Institute of General Medical Sciences (R01 GM123330)
- National Center for Advancing Translational Sciences (TL1 TR002533, UL1 TR003017, UM1 TR004399)
- National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK093903)
- National Institute of Environmental Health Sciences (P30 ES005022, T32 ES029074)
This publication has 35 references indexed in Scilit:
- The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA studyEuropean Journal of Cancer, 2022
- Population Pharmacokinetic–Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on NephrotoxicityJournal of Pharmaceutical Sciences, 2016
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Transgenic Expression of the Human MRP2 Transporter Reduces Cisplatin Accumulation and Nephrotoxicity in Mrp2-Null MiceThe American Journal of Pathology, 2014
- Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)Toxicology and Applied Pharmacology, 2013
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational ModelingJournal of Medicinal Chemistry, 2012
- Profiling of a Prescription Drug Library for Potential Renal Drug–Drug Interactions Mediated by the Organic Cation Transporter 2Journal of Medicinal Chemistry, 2011
- Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicityBiochemical Pharmacology, 2010
- Cisplatin1999
- Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusionCancer Chemotherapy and Pharmacology, 1980